Report produced by the U.S. Department of Health and Human Services (HHS) Office on Women's Health (OWH), examining the prevention, treatment, and recovery issues for women who misuse, have use disorders, and/or overdose on opioids
Public Health Agency of Canada, June 2021.
This update includes data on deaths, hospitalizations and Emergency Medical Services responses involving opioids and/or stimulants between January 2016 and December 2020, where available.
Update on the state of the science on pain research, care, and education and to identify actions to respond to the opioid epidemic, incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.
Special Journal Feature: Health Promotion and Chronic Disease Prevention Canada June 2018
This analysis used data from the Hospital Morbidity Database and the National Ambulatory Care Reporting System to determine the number of opioid poisoning hospitalizations and emergency department visits in Canada.
Ontario delisted high-strength fentanyl, hydromorphone and morphine from the public drug formulary for non-palliative care prescribers on 31 January, 2017. Our aim is to assess the early impact of this policy on prescribing patterns and to examine whether this impact varied by prescriber type, opioid type and opioid strength.